A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : 5ARI / 5alpha-reductase inhibitor

[Related PubMed/MEDLINE]
Total Number of Papers: 96
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   5ARI  (>> Co-occurring Abbreviation)
Long Form:   5alpha-reductase inhibitor
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2022 5-Alpha Reductase Inhibitor Use and Prostate Cancer Prevention: A Victim of the Times? ---
2022 5-Alpha Reductase Inhibitors and Prostate Cancer Mortality among Men with Regular Access to Screening and Health Care. CI
2022 5alpha-reductase inhibitors and the risk of bladder cancer in a large, population-based cohort. BC, CI, HR
2022 A Novel Nomogram Based on Initial Features to Predict BPH Progression. BPH, LUTS, PSA
2022 Depression risk associated with the use of 5alpha-reductase inhibitors versus alpha-blockers: A retrospective cohort study in South Korea. AB, BPH, HR, PS
2022 Inhibition of Human Prostate and Bladder Smooth Muscle Contraction, Vasoconstriction of Porcine Renal and Coronary Arteries, and Growth-Related Functions of Prostate Stromal Cells by Presumed Small Molecule Galphaq/11 Inhibitor, YM-254890. BPH, LUTS, OAB
2022 Post-Finasteride Syndrome. Literature Review. BPH, PFS
2022 Predictive factors for alpha blocker use after transurethral prostatectomy: Can preoperative urodynamic outcome predict alpha blocker medication after surgery? IPSS, OR, PSA, UDS
2022 Presence of Codes for Indication for Use in Clinical Practice Research Datalink Aurum: An Assessment of Benign Prostatic Hyperplasia Treatments. AB, CPRD
10  2022 Risk Factors for Transurethral Coagulation for Hemostasis During Holmium Laser Enucleation of the Prostate. BPH, CI, HoLEP, ORs, PSA, TPV, TUC, TZV
11  2021 5alpha-Reductase Inhibitors Are Associated with Reduced Risk of SARS-CoV-2 Infection: A Matched-Pair, Registry-Based Analysis. ARR, SARS-CoV-2
12  2021 A prospective clinical and transcriptomic feasibility study of oral-only hormonal therapy with radiation for unfavorable prostate cancer in men 70 years of age and older or with comorbidity. ADT, AR, HRQoL, LHRH, oADT, PCa, RT, SOC
13  2021 Potentially Inappropriate Prescribing for Prostatic Hyperplasia in Older Persons. BPH, EAU, SmPC
14  2021 Real-world therapeutic management and evolution of patients with benign prostatic hyperplasia in primary care and urology in Spain. BPH, LUTS
15  2021 The association of new-onset diabetes mellitus and medical therapy for benign prostatic hyperplasia: A population-based study. AB, BPH, CI, DM, HR
16  2021 The effect of pharmacotherapy on prostate volume, prostate perfusion and prostate-specific antigen (prostate morphometric parameters) in patients with lower urinary tract symptoms and benign prostatic obstruction. A systematic review and meta-analysis. PDE5, PRISMA, PSA, RCTs, SMD, TPV, TZV
17  2021 The impact of preoperative lower urinary tract symptoms medication on the functional performance of holmium laser enucleation of the prostate. BPO, HoLEP, LUTS, PVR, QoL
18  2021 The prostaglandin pathway is activated in patients who fail medical therapy for benign prostatic hyperplasia with lower urinary tract symptoms. BPH, GPCRs, I-BPH, LUTS, MTOPS, PG, S-BPH, TZ
19  2020 5-Alpha reductase inhibitors in androgenetic alopecia: Shifting paradigms, current concepts, comparative efficacy, and safety. 5-AR, AGA, DHT
20  2020 Efficacy and safety of Finasteride (5 alpha-reductase inhibitor) monotherapy in patients with benign prostatic hyperplasia: A critical review of the literature. AEs, IPPS, LUTS/BPH, PSA, PV, PVR, RCTs, SMD, voiding IPSS
21  2020 Finasteride and Its Potential for the Treatment of Female Pattern Hair Loss: Evidence to Date. FPHL
22  2020 Macular Abnormalities Associated With 5alpha-Reductase Inhibitor. ---
23  2020 National Trends in the Management of Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia. ABs, BPH, LUTSs, MISTs
24  2020 Pharmacological treatment of lower urinary tract symptoms in benign prostatic hyperplasia: consequences on sexual function and possible endocrine effects. BPH, LUTS, PDE5i
25  2020 Pharmacology of the lower urinary tract: update on LUTS treatment. AE, LUTS
26  2020 Synthesis and Study of Some 17a-aza-D-homo Steroids as 5alpha-Reductase Inhibitors. ---
27  2020 Ultrasound prostate parameters as predictors of successful trial without catheter after acute urinary retention in patients ongoing medical treatment for benign prostatic hyperplasia: a prospective multicenter study. ABs, AUR, BMI, BWT, TWOC
28  2019 5-ARI induces autophagy of prostate epithelial cells through suppressing IGF-1 expression in prostate fibroblasts. BPH, IGF-1, LUTS
29  2019 Accuracy of the preoperative PSA level for predicting clinically significant incidental transitional zone-prostate cancer before endoscopic enucleation of very large adenoma. EEP, TZ-PCa
30  2019 Association between 5alpha-reductase inhibitors therapy and incidence, cancer-specific mortality, and progression of prostate cancer: evidence from a meta-analysis. CIs, RR
31  2019 Pharmacological interventions for treating chronic prostatitis/chronic pelvic pain syndrome. BTA, CI, MD, NIH-CPSI, QoE, RR, TCM
32  2019 Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia. AB, AE, BPH, BPHII, CENTRAL, CI, MD, NIH, PDEI, RCT, RR, WHO
33  2019 Possible role of 5-alpha reductase inhibitors in non-invasive bladder urothelial neoplasm: multicenter study. ---
34  2019 The effect of 5 alpha-reductase inhibitor therapy on prostate cancer detection in the era of multi-parametric magnetic resonance imaging. CI, csPCa, mpMRI, MRI, OR, PCa, TRUS
35  2018 Computer vision detects subtle histological effects of dutasteride on benign prostate. CI
36  2018 Deregulation of ATG9A by impaired AR signaling induces autophagy in prostate stromal fibroblasts and promotes BPH progression. AR, BPH
37  2018 Prostate-Specific Antigen Kinetics Following 5alpha-Reductase Inhibitor Treatment May Be a Useful Indicator for Repeat Prostate Biopsy. PSA
38  2018 Use of 5alpha-reductase inhibitors for benign prostate hypertrophy and risk of high grade prostate cancer: a French population-based study. BPH, CI
39  2017 A prospective randomised placebo-controlled study of the impact of dutasteride/tamsulosin combination therapy on sexual function domains in sexually active men with lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH). BPH, FDC, LUTS, MSHQ, SE
40  2017 Differences in the Treatment of Benign Prostatic Hyperplasia: Comparing the Primary Care Physician and the Urologist. ---
41  2017 Dihydrotestosterone: Biochemistry, Physiology, and Clinical Implications of Elevated Blood Levels. ---
42  2017 Optimising patient outcomes with photoselective vaporization of the prostate (PVP): a review. BPH, LUTS, PVP, TURP
43  2017 Prognostic value of urinary prostate cancer antigen 3 (PCA3) during active surveillance of patients with low-risk prostate cancer receiving 5alpha-reductase inhibitors. AS, PCA3
44  2017 Rationale and design of the CANARI study: a case-control study investigating the association between prostate cancer and 5-alpha-reductase inhibitors for symptomatic benign prostate hypertrophy by linking SNIIRAM and pathology laboratories in a specific region in France. BPH, PCa
45  2017 Re: Impact of Combination Therapy 5-Alpha Reductase Inhibitors (5-ARI) plus Alpha-Blockers (AB) on Erectile Dysfunction and Decrease of Libido in Patients with LUTS/BPH: A Systematic Review with Meta-Analysis. AB
46  2017 The Genomic Alterations of 5alpha-Reductases and Their Inhibitor Finasteride's Effect in Bladder Cancer. 5-AR, UBC
47  2017 Use of 5-alpha-reductase inhibitors as alternatives to luteinizing-hormone releasing hormone (LHRH) analogs or anti-androgens for prostate downsizing before brachytherapy. GnRH, LHRH, PAI
48  2016 Impact of combination therapy 5-alpha reductase inhibitors (5-ARI) plus alpha-blockers (AB) on erectile dysfunction and decrease of libido in patients with LUTS/BPH: a systematic review with meta-analysis. AB, BPO, ED, LA, LUTS, RCT
49  2016 NF-kappaB and androgen receptor variant 7 induce expression of SRD5A isoforms and confer 5ARI resistance. AR, AR-V7, AUASS, BPH, LUTS, TRUS
50  2016 Patterns of Care for Newly Diagnosed Benign Prostatic Hyperplasia in the United States. ---
51  2015 5-alpha reductase inhibitors, benign prostatic hyperplasia, and risk of male breast cancer. BPH, CI, HR, TURP
52  2015 Combination of 5alpha-reductase inhibitor with combined androgen blockade (CAB) as a novel cytoreductive regimen before prostate brachytherapy: Ultra-CAB. CAB
53  2015 NF-kappaB and androgen receptor variant expression correlate with human BPH progression. AR-FL, AR-V, AR-V7, BPH, NF-kappaB
54  2015 Patient's and physician's behavior on the management of benign prostatic hyperplasia among the patients at the risk of clinical progression. A multicenter noninterventional trial in Slovakia by "Prostate and Expectations of Treatment: Epidemiology Research" (PETER) study group. LUTS, PETER, RP
55  2015 Risk of Fractures and Falls during and after 5-alpha Reductase Inhibitor Use: A Nationwide Cohort Study. HR
56  2015 [Effect and safety of GreenLight HPS 120-W laser vaporization of the prostate for different benign prostatic hyperplasia populations]. AUR, PV, PVP, TURP
57  2014 Alcohol intake increases high-grade prostate cancer risk among men taking dutasteride in the REDUCE trial. CIs, OR, ORs, PCa
58  2014 Efficacy and safety of 120-W GreenLight High-Performance System laser photo vaporization of the prostate: 3-year results with specific considerations. AUR, BPH, HPS, PVP, TURP
59  2014 Long-term use of 5alpha-reductase inhibitors and the risk of male breast cancer. ---
60  2014 Potent increased risk of the initiation of DNA replication in human prostate cancer with the use of 5alpha-reductase inhibitors. DHT, PCa, pre-RC
61  2014 Short-term pretreatment with a dual 5alpha-reductase inhibitor before bipolar transurethral resection of the prostate (B-TURP): evaluation of prostate vascularity and decreased surgical blood loss in large prostates. B-TURP, CD34, DHT, Hb, Ht, MVD, PSA, VEGF
62  2014 Surgical intervention for symptomatic benign prostatic hyperplasia is correlated with expression of the AP-1 transcription factor network. BPH/LUTS
63  2013 5alpha-reductase inhibition suppresses testosterone-induced initial regrowth of regressed xenograft prostate tumors in animal models. ADT, IADT
64  2013 Active surveillance of very-low-risk prostate cancer in the setting of active treatment of benign prostatic hyperplasia with 5alpha-reductase inhibitors. PCa
65  2013 Associations of obesity, physical activity and diet with benign prostatic hyperplasia and lower urinary tract symptoms. BPH, LUTS
66  2013 Clinical progression, acute urinary retention, prostate-related surgeries, and costs in patients with benign prostatic hyperplasia taking early versus delayed combination 5alpha-reductase inhibitor therapy and alpha-blocker therapy: a retrospective analysis. AB, AUR, BPH, PSA
67  2013 Medical management of lower urinary tract symptoms in men with benign prostatic enlargement. LUTS, PSA
68  2013 Peripheral zone prostate-specific antigen density: an effective parameter for prostate cancer prediction in men receiving 5alpha-reductase inhibitors. AUC, PCa, PSA, PSAD, PZ, ROC, TZ
69  2013 Progression of lower urinary tract symptoms after discontinuation of 1 medication from 2-year combined alpha-blocker and 5-alpha-reductase inhibitor therapy for benign prostatic hyperplasia in men--a randomized multicenter study. TPV, TURP
70  2013 Side Effects of 5-Alpha Reductase Inhibitors: A Comprehensive Review. AEs, ED, EjD
71  2013 Systematic review of combination drug therapy for non-neurogenic male lower urinary tract symptoms. LUTS
72  2013 Tamsulosin treatment for benign prostatic hyperplasia and risk of severe hypotension in men aged 40-85 years in the United States: risk window analyses using between and within patient methodology. ---
73  2013 Use of 5alpha-reductase inhibitors for lower urinary tract symptoms and risk of prostate cancer in Swedish men: nationwide, population based case-control study. ---
74  2012 alpha-blocker monotherapy and alpha-blocker plus 5-alpha-reductase inhibitor combination treatment in benign prostatic hyperplasia; 10 years' long-term results. alpha-blocker, AUR, BPH, PSA, PV
75  2012 Effect of treatment with 5-alpha reductase inhibitors on progression in monitored men with favourable-risk prostate cancer. 5ARIs, AS, CI, HR
76  2012 Endocrine prevention and treatment of prostate cancer. DHT
77  2011 Association of 5alpha-reductase inhibitor use and pathological features of prostate cancer in men undergoing radical prostatectomy. PCa
78  2011 Battling prostate cancer with 5-alpha-reductase inhibitors: a pyrrhic victory? ---
79  2011 Benign prostatic hyperplasia and lower urinary tract symptoms: evidence and approaches for best case management. BPH, IPSS, LUTS
80  2011 Changes in sexual function in benign prostatic hyperplasia patients taking dutasteride: 1-year follow-up results. AEs, BPH, EF
81  2011 Clinical and economic impact of early versus delayed 5-alpha reductase inhibitor therapy in men taking alpha blockers for symptomatic benign prostatic hyperplasia. BPH
82  2011 Risk stratification for benign prostatic hyperplasia (BPH) treatment. BPH
83  2010 Prospective factor analysis of alpha blocker monotherapy failure in benign prostatic hyperplasia. alpha-blocker, BPH, IPSS, PSA, PVR, ROC, TURP
84  2010 Prostate cancer detection and dutasteride: utility and limitations of prostate-specific antigen in men with previous negative biopsies. PCa, PSA
85  2010 The influence of family history on prostate cancer risk: implications for clinical management. ---
86  2009 Dutasteride and bicalutamide in patients with hormone-refractory prostate cancer: the Therapy Assessed by Rising PSA (TARP) study rationale and design. CRPC, DHT, TARP
87  2008 5alpha-Reductase inhibitor treatment of prostatic diseases: background and practical implications. ---
88  2008 Management of benign prostatic hyperplasia by the primary care physician in the 21st century: the new paradigm. BPH, LUTS, PSA, TURP
89  2008 Management of symptomatic benign prostatic hyperplasia--today. BPH, IPSS, LUTS, PSA
90  2007 Blood loss and postoperative complications associated with transurethral resection of the prostate after pretreatment with dutasteride. BPH, DHT, Hb, MVD, TURP
91  2007 Delay in the progression of low-risk prostate cancer: rationale and design of the Reduction by Dutasteride of Clinical Progression Events in Expectant Management (REDEEM) trial. PSA, QoL, REDEEM
92  2007 Understanding patient and physician perceptions of benign prostatic hyperplasia in Europe: The Prostate Research on Behaviour and Education (PROBE) Survey. BPH, PROBE, PSA
93  2007 [Benign prostate hyperplasia: success and limitations of pharmacological therapy]. BPH
94  2006 [Effect of dutasteride on reduction of intraoperative bleeding related to transurethral resection of the prostate]. BPH, TURP
95  2005 The effects of 5alpha-reductase inhibitors on the natural history, detection and grading of prostate cancer: current state of knowledge. PCPT
96  2003 Alpha-blocker therapy can be withdrawn in the majority of men following initial combination therapy with the dual 5alpha-reductase inhibitor dutasteride. DT36